Financial Data and Key Metrics Changes - For 2025, adjusted earnings per share (EPS) was $6.98, representing an 8.7% increase year-over-year, primarily due to higher revenue and adjusted operating income [16][17] - Adjusted gross margin for 2025 was 63.7%, a decrease of 200 basis points year-over-year, attributed to tariffs, the acquisition of Vascular Intervention, and increased logistics costs [15][16] - Adjusted operating margin for 2025 was 22.7%, reflecting a 230 basis point decrease year-over-year due to gross margin pressure and higher operating expenses [15][16] Business Line Data and Key Metrics Changes - Vascular revenue increased 2.4% year-over-year to $472.7 million, driven by growth in Central Access, hemostatic, and atomization products [14] - Interventional revenue was $427.5 million, an increase of 8.1%, supported by a broad portfolio [14] - Surgical revenue was $219.3 million, reflecting a 3.2% increase, influenced by volume-based procurement in China [14][15] Market Data and Key Metrics Changes - Continuing operations delivered 4.7% pro forma adjusted constant currency revenue growth in the second half of 2025, establishing a solid foundation for future growth [28][22] - Pro forma adjusted constant currency revenue growth for 2026 is expected to be in the range of 4.5%-5.5% [22] Company Strategy and Development Direction - The company is undergoing a transformation to optimize its portfolio and focus on high-growth areas, with plans to return significant capital to shareholders through a $1 billion share repurchase program [5][27] - The strategic divestitures of Acute Care, Interventional Urology, and OEM businesses are expected to close in the second half of 2026, with net proceeds of approximately $1.8 billion to be used for share repurchases and debt repayment [7][20] - R&D investment for RemainCo is expected to represent approximately 8% of sales, up from 5% historically, indicating a focus on product innovation [8][71] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid-single-digit revenue growth and significant increases in adjusted EPS in 2027 and beyond, driven by cost mitigation and capital deployment actions [30][50] - The company is actively managing stranded costs of approximately $90 million associated with the divestitures, with plans to offset these through transition service agreements and restructuring initiatives [9][24] Other Important Information - The company is currently in a CEO search process, focusing on candidates with experience in high-growth, mid-size organizations operating in global healthcare settings [51] - A restructuring plan has been approved to eliminate stranded costs and streamline operations, targeting approximately $50 million in annual pre-tax savings [24][30] Q&A Session Summary Question: Use of proceeds from divestitures - The company plans to allocate $1 billion for share repurchases and approximately $800 million for debt repayment, primarily targeting the deferred draw revolver from the Bison acquisition [33] Question: Restructuring savings impact on EPS guidance - Some restructuring savings are included in the EPS guidance range of $6.25-$6.55 for 2026, with additional savings expected post-2026 [34] Question: Confidence in revenue growth for 2026 - The company is confident in its growth trajectory due to sales synergies and easier comparisons in the second half of 2026, despite some ongoing volume-based procurement impacts [81] Question: BIOTRONIK integration update - The integration of the BIOTRONIK sales force is progressing well, with no significant talent losses and opportunities for revenue synergies identified [69][70] Question: Future margin expansion post-transition service agreements - The company aims to mitigate stranded costs and leverage operational efficiencies to improve margins, with expectations for continued growth in earnings and margins beyond 2026 [75][76]

Financial Data and Key Metrics Changes - For 2025, adjusted earnings per share (EPS) was $6.98, representing an 8.7% increase year-over-year, primarily due to higher revenue and adjusted operating income, including the impact of the Vascular Intervention acquisition [16][17] - Adjusted gross margin for 2025 was 63.7%, a decrease of 200 basis points year-over-year, attributed to tariffs, the addition of the Vascular Intervention acquisition, and increased logistics costs [15][16] - Adjusted operating margin for 2025 was 22.7%, reflecting a 230 basis point decrease due to gross margin pressure and higher operating expenses [16] Business Line Data and Key Metrics Changes - Vascular revenue increased 2.4% year-over-year to $472.7 million, driven by growth in Central Access, hemostatic, and atomization products [14] - Interventional revenue was $427.5 million, an increase of 8.1%, supported by a broad Interventional portfolio [14] - Surgical revenue was $219.3 million, reflecting a 3.2% increase, impacted by volume-based procurement in China [14] Market Data and Key Metrics Changes - Continuing operations delivered 4.7% pro forma adjusted constant currency revenue growth in the second half of 2025, establishing a solid foundation for future mid-single-digit revenue growth [22][28] - Pro forma adjusted constant currency revenue growth guidance for 2026 is expected to be in the range of 4.5%-5.5% [22] Company Strategy and Development Direction - The company is undergoing a transformation to optimize its portfolio, focusing on becoming a more streamlined medical technologies leader [27] - Strategic divestitures of the Acute Care, Interventional Urology, and OEM businesses are expected to close in the second half of 2026, with net proceeds of approximately $1.8 billion to be used for share repurchases and debt reduction [7][20][30] - R&D investment for RemainCo is expected to represent approximately 8% of sales, up from about 5% historically, indicating a focus on product innovation [8][71] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving adjusted EPS guidance for 2026 in the range of $6.25-$6.55, despite the impact of stranded costs related to divestitures [9][21] - The company anticipates significant improvements in margins and adjusted EPS in 2027 and beyond, driven by capital deployment actions and cost-saving initiatives [30][50] Other Important Information - The company is actively conducting a CEO search following the transition of leadership, focusing on candidates with experience in high-growth organizations [5][51] - A restructuring plan has been approved to mitigate approximately $50 million in stranded costs, aimed at streamlining operations and improving long-term cost structure [24][30] Q&A Session Summary Question: Use of proceeds from divestitures - The company plans to allocate $1 billion for share repurchases and approximately $800 million for debt repayment, primarily targeting the deferred draw revolver from the BIOTRONIK acquisition [33] Question: Restructuring savings impact on EPS guidance - Some restructuring savings are included in the EPS guidance for 2026, with additional savings expected post-2026 [34] Question: Confidence in revenue growth for 2026 - Confidence in revenue growth is based on anticipated sales synergies and easier comparisons in the second half of 2026, as the impact of volume-based procurement is expected to lessen [81]

Core Insights - TDS has transitioned from a significant loss to profitability, indicating operational stabilization after years of volatility [10] - Silver Point Capital has reduced its stake in TDS, selling 1.3 million shares, which reflects a decrease in the fund's exposure to the company [2][11] Company Overview - TDS reported a total revenue of $4.9 billion and a net income of -$143.2 million for the trailing twelve months (TTM) [4] - The company has a dividend yield of 0.4% and its stock price was $39.41 as of the latest report [4] Recent Performance - In the third quarter, TDS generated $308.5 million in revenue, a 6% decrease year-over-year, but achieved a net income of $40.2 million, recovering from a $100.4 million loss in the prior year [12] - The company has initiated a share repurchase program, buying back over 1 million shares and approving a new $500 million buyback authorization, signaling management's confidence in its fiber-first strategy [12] Market Position - TDS operates as a leading U.S. telecommunications provider, offering a diversified portfolio that includes wireless, broadband, and managed services [6][9] - The company serves a wide range of customers, including individual consumers, businesses, and government entities, focusing on integrated connectivity solutions [6][9] Investment Implications - The reduction of Silver Point Capital's stake in TDS, now representing 2.4% of the fund's reportable assets under management (AUM), places TDS outside the fund's top five holdings [3][11] - Despite the recent profitability, TDS's stock remains discounted compared to its mid-2000s highs, which may influence long-term investor sentiment [10]

Financial Data and Key Metrics Changes - Q1 2025 was described as a solid start to the year, with IAC reaffirming full year 2025 adjusted EBITDA guidance across all businesses [5][16] - DDM grew digital revenues by 7% in Q1 and increased EBITDA by 46%, excluding a one-time lease gain [7][16] - The company repurchased 4,500,000 shares and increased share repurchase authorization by 10,000,000 shares [5][11] Business Line Data and Key Metrics Changes - DDM's licensing revenue grew by 30%, driven by the OpenAI license and strong performance at Apple News [34] - Performance marketing also showed strong growth at 11% [34] - The Daily Beast achieved a revenue growth of 72% while reaching profitability [8] Market Data and Key Metrics Changes - Core traffic for DDM declined by 3% in Q1, with digital advertising only up by 1% due to fewer impressions available for programmatic sales [33] - Premium demand in advertising remained stable, with strength in pharma, tech, and beauty offsetting weaknesses in food and beverage [15][33] - Programmatic pricing softened, running flat year over year after previously increasing [15] Company Strategy and Development Direction - The company is focused on executing growth across its businesses and capital allocation, including share buybacks and M&A opportunities [10][11] - IAC is pursuing strategic divestitures of smaller holdings to free up capital and simplify operations [12] - The company aims to create equity value and reduce the discount at which its shares are trading [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding consumer spending, noting solid performance in DDM despite weak consumer confidence [14][16] - The macroeconomic outlook remains uncertain, but the company is monitoring trends closely and reaffirming guidance based on current business performance [16] - Management highlighted the importance of focusing on execution and controlling what can be controlled in an unpredictable environment [16] Other Important Information - The company reached an agreement to settle litigation related to the match separation, requiring only a $200,000 contribution beyond insurance coverage [8] - IAC has $800 million in net operating losses (NOLs) that could offset taxable gains on its MGM stake [9] Q&A Session Summary Question: Key priorities for 2026 TDM revenue growth and capital allocation - Management discussed excitement about 2026, highlighting projects like the People app and MyRecipes, and emphasized the importance of capital allocation between share repurchases and M&A [18][20][25] Question: Q1 trends in DDM Digital revenue - Management noted that Q1 faced tough comparisons and a decline in core traffic, but March showed solid growth in digital advertising [30][32] Question: DDM cash flow dynamics - Management explained that DDM can dividend cash to IAC if leverage ratios are below four times total debt to EBITDA, enhancing financial flexibility [43] Question: Appointment of Jim Lawson as President of Decipher - Management expressed excitement about Jim Lawson's appointment, emphasizing his experience and the potential for Decipher Plus to drive growth [46][48] Question: Impact of Google phasing out cookies - Management indicated that the cookie phase-out is not a significant concern, as their contextual targeting capabilities remain strong [58][60] Question: Strategic priorities for Care.com - Management outlined three core priorities for Care: improving product matching, optimizing pricing and packaging, and enhancing marketing efforts [100][104]